What biotech could bring in 2025

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

In this, my last newsletter in 2024, I offer some thoughts on biotech in 2025.

I’m taking a two-week break, so look for me again on Jan. 9. I hope you all have a Happy Hanukkah and a Merry Christmas.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Pfizer and Novartis chiefs lead pharma’s CEO influencers on social media, analysis finds

When it comes to pharma CEOs as social influencers, Pfizer’s Albert Bourla is a perfect 10 compared to his peers. Novartis CEO Vas Narasimhan is

February 24, 2024

Pfizer and Lilly want to sell you drugs directly

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, and thank

August 27, 2024

Sotio terminates three trials studying its IL-15 superagonist due to ‘insufficient efficacy’

Czech biotech Sotio is immediately scrapping three clinical trials of its interleukin-15 superagonist called nanrilkefusp alfa after interim data showed “insufficient efficacy.” “While we are

October 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.